Skip to content
Home
About
ABOUT
About Overview
Leadership
Science
Pipeline
Patient & Caregiver Resources
Resources
Clinical Trials & Expanded Access Policy
Spinal Cord Injury
Investors
Investors
Stock Information
Financial Information
Corporate Governance
News Releases
Events & Presentations
Analyst Coverage
In The Media
Contact Us
Home
About
ABOUT
About Overview
Leadership
Science
Pipeline
Patient & Caregiver Resources
Resources
Clinical Trials & Expanded Access Policy
Spinal Cord Injury
Investors
Investors
Stock Information
Financial Information
Corporate Governance
News Releases
Events & Presentations
Analyst Coverage
In The Media
Contact Us
Home
About
ABOUT
About Overview
Leadership
Science
Pipeline
Patient & Caregiver Resources
Resources
Clinical Trials & Expanded Access Policy
Spinal Cord Injury
Investors
Investors
Stock Information
Financial Information
Corporate Governance
News Releases
Events & Presentations
Analyst Coverage
In The Media
Contact Us
Home
About
ABOUT
About Overview
Leadership
Science
Pipeline
Patient & Caregiver Resources
Resources
Clinical Trials & Expanded Access Policy
Spinal Cord Injury
Investors
Investors
Stock Information
Financial Information
Corporate Governance
News Releases
Events & Presentations
Analyst Coverage
In The Media
Contact Us
2022
01 • 10 • 2022
NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership with Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitation
01 • 04 • 2022
NervGen Pharma Applauds President Biden Signing Defense Bill / Department of Defense now able to Move Forward on Brain Plasticity Research
No posts found
1
2
3
4
Next